Topics
Researcher Oki from Screening BU to Deliver an Oral Presentation at the 52nd Annual Workshop of the Japanese Society of Toxicology
2025.06.30
Our researcher, Hideyuki Oki from the Screening Business Unit, will deliver an oral presentation at the 52nd Annual Meeting of the Japanese Society of Toxicology, to be held from July 2 to 4, 2025, at the Okinawa Convention Center in Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.
Conference Name: the 52nd Annual Meeting of the Japanese Society of Toxicology
Date & Time: Wednesday, July 2nd, 14:15 – 15:45 (JST)
Location: Room5, Okinawa Convention Center, Japan
Title: Recent Advances in Structural Analysis Techniques for Target Molecules
Registration number: S11-1: Symposium 11
Presenter: Hideyuki Oki, Screening Business Unit
Presentation Summary
Recent advancements in structural analysis technology have been remarkable, enabling not only the structural analysis of drug target molecules but also the elucidation of mechanisms of action related to toxicity. Furthermore, the dramatic progress in cryo-electron microscopy (cryo-EM) technology has made it possible to perform detailed structural analysis of membrane proteins. The three-dimensional structural information obtained through these technological innovations provides crucial insights for addressing toxicity issues in drug discovery research. In this presentation, I will introduce the latest technological advancements in X-ray crystallography and cryo-electron microscopy, along with case studies of structural analysis related to toxicity.
Axcelead DDP’s Soulution
Cases where structural information can be utilized are closer than you might think. For example, kinase inhibitors often have low selectivity for kinases other than their target molecules, which can lead to side effects and toxicity. In such instances, it is possible to identify the problematic kinases and resolve these issues through rational approaches based on their three-dimensional structures. Our company offers a wide range of methods to address these cases, including various biochemical approaches such as kinase panels and biophysical techniques like X-ray crystallography. Should you experience any issues in drug discovery research, please feel free to consult with us.
Hideyuki Oki, Screening Business Unit
Hideyuki Oki joined Takeda Pharmaceutical Company. He has been involved in drug discovery research from the perspective of structural biology, engaging in protein X-ray crystallography, drug design using computational chemistry, and interaction analysis using NMR and MS. Following his tenure at Takeda San Diego and serving as the team leader of the Biophysical Analysis team, he transferred to Axcelead Drug Discovery Partners Inc. in 2017.